KSCCM
Search
- Page Path
- HOME > Search
Case Reports
- Cardiology
- Catecholamine-Induced Cardiomyopathy associated with Neuroblastoma and Treated with Extracorporeal Membrane Oxygenation as a Bridge to Recovery
- Junggu Yi, Si Oh Kim, Jun-mo Park, Sung-hye Byun, Hoon Jung, Seong Wook Hong
- Korean J Crit Care Med. 2015;30(4):299-302. Published online November 30, 2015
- DOI: https://doi.org/10.4266/kjccm.2015.30.4.299
- 4,988 View
- 89 Download
- 1 Crossref
-
Abstract
PDF - Catecholamine-induced cardiomyopathy associated with neuroblastoma is rarely reported. We report a case of catecholamine-induced cardiomyopathy associated with neuroblastoma in a 33-month-old female that was treated with extracorporeal membrane oxygenation (ECMO). She was tentatively diagnosed with acute myocarditis and presented with hypertension. Because of rapid patient deterioration despite pharmacological treatments, ECMO was applied. ECMO can be helpful in cases of catecholamine-induced cardiomyopathy associated with neuroblastoma.
-
Citations
Citations to this article as recorded by
- COVID-19 and cardiovascular disease: manifestations, pathophysiology, vaccination, and long-term implication
Adel Abdel Moneim, Marwa A. Radwan, Ahmed I. Yousef
Current Medical Research and Opinion.2022; 38(7): 1071. CrossRef
- COVID-19 and cardiovascular disease: manifestations, pathophysiology, vaccination, and long-term implication
- Cardiology
- Torsades de Pointes during Treatment of Tachycardia-Induced Cardiomyopathy
- Dong Kyu Lee, Il Hwan Ryu, Ji Hyung Yoo, Su A Yun, Sang Hyun Park, Ki Woon Kang, Won Ho Kim, Yu Jeong Choi, Kyung Tae Jung, Jung Yeon Chin
- Korean J Crit Care Med. 2014;29(1):19-22. Published online February 28, 2014
- DOI: https://doi.org/10.4266/kjccm.2014.29.1.19
- 5,440 View
- 71 Download
-
Abstract
PDF
- Tachycardia-induced cardiomyopathy is caused by persistent tarchyarrhythmias and is characterized by ventricular systolic dysfunction and congestive heart failure. Tachycardia-induced cardiomyopathy is usually reversible via treatment. The cornerstone in the management of disease in these patients is to achieve a normal heart rate. We report a torsades de pointes during treatment of tachycardia-induced cardiomyopathy. Intravenous magnesium sulfate and potassium were administrated, but torsades de pointes was repeated. After overdrive right ventricular pacing, torsades de pointes was terminated. Careful monitoring of the QT interval and serum electrolyte and drug levels in such patients is warranted during treatment of tachycardia-induced cardiomyopathy.
First
Prev
